Tag: dostarlimab-gxly
GSK announces significant survival results for Jemperli in endometrial cancer trial
In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from ... Read More
LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership with GSK, to evaluate the potential of ... Read More
GSK secures full Jemperli FDA approval for endometrial cancer treatment
Biopharma company GSK has secured the full approval of the US Food and Drug Administration (FDA) for its Jemperli (dostarlimab-gxly) drug for recurrent or advanced ... Read More